Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance.

ABSTRACT: The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase

SUBMITTER: Eltahla AA 

PROVIDER: S-EPMC4632376 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature